Company

Calliditas Therapeutics AB

Headquarters: Stockholm, Sweden

Employees: 66

OMX: CALTX

Market Cap

kr11.03 Billion

SEK as of July 1, 2024

US$1.04 Billion

Market Cap History

Calliditas Therapeutics AB market capitalization over time

Evolution of Calliditas Therapeutics AB market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Calliditas Therapeutics AB

Detailed Description

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. The company's lead product candidate is Nefecon, a oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) was founded in 2004 and is headquartered in Stockholm, Sweden.

Top 1-year algo backtest: +227.67%

$10,000 in September 2023 would now be $32,767 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Calliditas Therapeutics AB has the following listings and related stock indices.


Stock: OMX: CALTX wb_incandescent

Stock: FSX: LC8A wb_incandescent

Details

Headquarters:

Kungsbron 1, C8

Stockholm, 111 22

Sweden

Phone: 46 84 11 30 05